Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to acknowledge Prof Allan Hackshaw and Nicholas Counsell, medical statisticians at the Cancer Research UK and University College London Cancer Trials Centre, for review of statistical methods and performing toxicity/survival analyses, respectively. This study was endorsed by Cancer Research UK (reference C17077/A5667; clinicaltrials.gov no. NCT00562068) and co-ordinated by the Cancer Research UK and University College London Cancer Trials Centre. Schering AG pharmaceuticals provided initial study funding and supplied alemtuzumab free of charge. Sanofi continued this support in the later phases of the trial.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2019.1576870.